Alopexx Enterprises

About The Fund

Alopexx Enterprises is a venture capital firm based in Concord, Massachusetts, specializing in healthcare technology with a particular emphasis on oncology. They are focused on developing therapeutic solutions to combat microbial diseases and reduce the world's reliance on antibiotics through their subsidiary, Alopexx Immune Therapeutics. Alopexx's vision is to use a broad-spectrum immune approach to prevent a variety of microbial infections and other immune-mediated diseases using active vaccination and passive immunotherapies. Their approach aims to have a significant impact on personal and public health by offering alternatives to antibiotics, which tend to lead to the development of antimicrobial resistance (AMR). Alopexx has developed two immune therapeutics which operate without the use of antibiotics and therefore do not contribute to AMR. This is achieved by utilizing the host's immune system and avoiding the low-level excretion of antibiotics which can promote AMR. These immune therapeutics target PNAG (poly-N-acetyl glucosamine), a common component on the surface of microbial pathogens which is critical for adhesion and survival within the host. PNAG is widely distributed across various pathogens, found on the majority of fungal and bacterial microbes, making it an excellent target for broad-spectrum solutions. Alopexx has identified PNAG on over 75 separate microbial pathogens to date. Through its research and development, Alopexx is addressing the critical medical threat posed by the rise of AMR, a global issue acknowledged by health authorities including the CDC and World Health Organization. The company's therapeutic solutions pipeline includes the monoclonal antibody F598 and the vaccine AV0328, as well as other potential treatments targeting PNAG. Alopexx's commitment to battling AMR and developing sustainable, broad-spectrum immune-mediated treatments positions it at the forefront of healthcare innovation.